Summary
5.4100 -0.3000(-5.2539%)05/13/2024
Delcath Sys Inc (DCTH)
Delcath Sys Inc (DCTH)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.6932 | 10.2984 | 13.9165 | 23.2258 | 77.3994 | -6.0656 | -94.0250 | -99.3937 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 5.7300 | |
| Open | 5.8900 | |
| High | 5.8900 | |
| Low | 5.6638 | |
| Volume | 124,948 | |
| Change | -0.0400 | |
| Change % | -0.6932 | |
| Avg Volume (20 Days) | 219,364 | |
| Volume/Avg Volume (20 Days) Ratio | 0.57 | |
| 52 Week Range | 2.25 - 7.99 | |
| Price vs 52 Week High | -28.29% | |
| Price vs 52 Week Low | 154.67% | |
| Range | -2.7165 | |
| Gap Up/Down | 0.0400 | |
Fundamentals | ||
| Market Capitalization (Mln) | 150 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 23.8000 | |
| Book Value | 1.5940 | |
| Earnings Per Share | -4.2520 | |
| EPS Estimate Current Quarter | -1.0800 | |
| EPS Estimate Next Quarter | -1.0500 | |
| EPS Estimate Current Year | -3.8800 | |
| EPS Estimate Next Year | -3.5700 | |
| Diluted EPS (TTM) | -4.2520 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -13.7431 | |
| Return on asset (TTM) | -0.6583 | |
| Return on equity (TTM) | -3.6436 | |
| Revenue TTM | 1,954,000 | |
| Revenue per share TTM | 0.3040 | |
| Quarterly Revenue Growth (YOY) | 0.1200 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 1,006,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.2823 | |
| Revenue Enterprise Value | 27.2456 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 7,356,290 | |
| Shares Float | 6,288,891 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 2.57 | |
| Institutions (%) | 28.06 | |
05/07 08:30 EST - PRNewsWire
Delcath Systems to Host First Quarter 2024 Earnings Call
QUEENSBURY, N.Y. , May 7, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 14, 2024, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2024.
Delcath Systems to Host First Quarter 2024 Earnings Call
QUEENSBURY, N.Y. , May 7, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 14, 2024, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2024.
04/23 10:56 EST - Zacks Investment Research
How Much Upside is Left in Delcath Systems (DCTH)? Wall Street Analysts Think 244.83%
The mean of analysts' price targets for Delcath Systems (DCTH) points to a 244.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
How Much Upside is Left in Delcath Systems (DCTH)? Wall Street Analysts Think 244.83%
The mean of analysts' price targets for Delcath Systems (DCTH) points to a 244.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
04/05 10:56 EST - Zacks Investment Research
Can Delcath Systems (DCTH) Climb 277.73% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 277.7% upside potential for Delcath Systems (DCTH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can Delcath Systems (DCTH) Climb 277.73% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 277.7% upside potential for Delcath Systems (DCTH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
04/02 13:01 EST - Zacks Investment Research
Delcath Systems (DCTH) Upgraded to Buy: What Does It Mean for the Stock?
Delcath Systems (DCTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Delcath Systems (DCTH) Upgraded to Buy: What Does It Mean for the Stock?
Delcath Systems (DCTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
03/26 09:41 EST - Zacks Investment Research
Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.86 per share a year ago.
Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates
Delcath Systems, Inc. (DCTH) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.86 per share a year ago.
12/19 10:11 EST - PennyStocks
Penny Stocks To Buy Now? 4 To Watch Before 2024
As we enter 2024, investors wonder if it will be another volatile year for stocks. Maybe we see some stabilization after 2023's ups and downs; maybe not.
Penny Stocks To Buy Now? 4 To Watch Before 2024
As we enter 2024, investors wonder if it will be another volatile year for stocks. Maybe we see some stabilization after 2023's ups and downs; maybe not.
11/21 15:01 EST - PennyStocks
Penny Stocks To Buy Today? 3 To Watch Before Thanksgiving
Is the stock market open on Thanksgiving? No, but that doesn't mean the shortened holiday week won't be packed with stock market moving catalysts.
Penny Stocks To Buy Today? 3 To Watch Before Thanksgiving
Is the stock market open on Thanksgiving? No, but that doesn't mean the shortened holiday week won't be packed with stock market moving catalysts.
11/17 18:40 EST - Seeking Alpha
Adoption Of Delcath's Hepzato Kit Will Snowball Quicker Than The Market Expects
Delcath's Hepzato Kit is the only liver directed FDA approved treatment for mUM, a rare form of cancer. It will launch in the US in January. The treatment had a 36.3% objective response rate, outperforming the best available alternative treatment by nearly triple. Delcath aims to expand the use of Hepzato Kit beyond uveal melanoma by targeting other indications such as intrahepatic cholangiocarcinoma and metastatic colorectal cancer.
Adoption Of Delcath's Hepzato Kit Will Snowball Quicker Than The Market Expects
Delcath's Hepzato Kit is the only liver directed FDA approved treatment for mUM, a rare form of cancer. It will launch in the US in January. The treatment had a 36.3% objective response rate, outperforming the best available alternative treatment by nearly triple. Delcath aims to expand the use of Hepzato Kit beyond uveal melanoma by targeting other indications such as intrahepatic cholangiocarcinoma and metastatic colorectal cancer.
11/13 22:07 EST - Seeking Alpha
Delcath Systems Inc. (DCTH) Q3 2023 Earnings Call Transcript
Delcath Systems Inc. (NASDAQ:DCTH ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants David Hoffman - General Counsel, Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, U.S. Interventional Oncology Conference Call Participants William Maughan - Canaccord Genuity Scott Henry - ROTH Capital Yale Jen - Laidlaw & Co. Operator Good day, and welcome to the Delcath Systems Reports Third Quarter Fiscal Year 2023 Financial Results. All participants will be in listen-only mode.
Delcath Systems Inc. (DCTH) Q3 2023 Earnings Call Transcript
Delcath Systems Inc. (NASDAQ:DCTH ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants David Hoffman - General Counsel, Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, U.S. Interventional Oncology Conference Call Participants William Maughan - Canaccord Genuity Scott Henry - ROTH Capital Yale Jen - Laidlaw & Co. Operator Good day, and welcome to the Delcath Systems Reports Third Quarter Fiscal Year 2023 Financial Results. All participants will be in listen-only mode.
11/06 16:30 EST - PRNewsWire
Delcath Systems to Host Third Quarter 2023 Results Call
NEW YORK , Nov. 6, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 13, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
Delcath Systems to Host Third Quarter 2023 Results Call
NEW YORK , Nov. 6, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 13, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
09/05 16:00 EST - PRNewsWire
Delcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023
NEW YORK , Sept. 5, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C Wainwright 25th Annual Global Investor Conference.
Delcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023
NEW YORK , Sept. 5, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C Wainwright 25th Annual Global Investor Conference.
08/15 08:05 EST - InvestorPlace
Why Is Delcath Systems (DCTH) Stock Up 72% Today?
Delcath Systems (NASDAQ: DCTH ) stock is rocketing higher on Tuesday after getting an update from the FDA. This has the FDA approving HEPZATO KIT.
Why Is Delcath Systems (DCTH) Stock Up 72% Today?
Delcath Systems (NASDAQ: DCTH ) stock is rocketing higher on Tuesday after getting an update from the FDA. This has the FDA approving HEPZATO KIT.
08/11 07:00 EST - Seeking Alpha
Delcath Systems: HEPZATO KIT Should Receive Approval On Aug 14 PDUFA
Delcath Systems recently passed FDA inspection without any manufacturing-related observations. The medical review for HEPZATO KIT has likely concluded successfully; FDA seems to have proposed a Black Box Warning, instead of asking for more clinical data. Recent sell-off due to API supplier concerns likely misplaced.
Delcath Systems: HEPZATO KIT Should Receive Approval On Aug 14 PDUFA
Delcath Systems recently passed FDA inspection without any manufacturing-related observations. The medical review for HEPZATO KIT has likely concluded successfully; FDA seems to have proposed a Black Box Warning, instead of asking for more clinical data. Recent sell-off due to API supplier concerns likely misplaced.
08/03 08:30 EST - PRNewsWire
Delcath Systems to File Its Second Quarter 2023 10-Q the Week of August 7 and Expects to Host a Conference Call the Following Week
NEW YORK , Aug. 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that it plans to report the Company's 2Q23 earnings and issue its Form 10-Q the week of August 7, 2023. Subsequently, shortly after the FDA's decision on its HEPZATO™ KIT's new drug application ("NDA") resubmission, Delcath expects to hold a conference call to review the quarter and the details of the FDA action.
Delcath Systems to File Its Second Quarter 2023 10-Q the Week of August 7 and Expects to Host a Conference Call the Following Week
NEW YORK , Aug. 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that it plans to report the Company's 2Q23 earnings and issue its Form 10-Q the week of August 7, 2023. Subsequently, shortly after the FDA's decision on its HEPZATO™ KIT's new drug application ("NDA") resubmission, Delcath expects to hold a conference call to review the quarter and the details of the FDA action.
06/01 03:00 EST - Seeking Alpha
Delcath Systems Is Prepared For A U.S. Commercial Launch
Delcath Systems is close to gaining FDA approval for its HEPZATO KIT, a minimally invasive liver cancer treatment. The company is well-funded and prepared for commercial operations in the U.S. and Europe, with plans to partner with medical centers and expand into other cancer treatments. Delcath faces risks such as maintaining FDA approval, establishing insurance reimbursement rates, and competition from other companies developing similar products.
Delcath Systems Is Prepared For A U.S. Commercial Launch
Delcath Systems is close to gaining FDA approval for its HEPZATO KIT, a minimally invasive liver cancer treatment. The company is well-funded and prepared for commercial operations in the U.S. and Europe, with plans to partner with medical centers and expand into other cancer treatments. Delcath faces risks such as maintaining FDA approval, establishing insurance reimbursement rates, and competition from other companies developing similar products.
05/12 10:13 EST - Seeking Alpha
Delcath Systems (DCTH) Q1 2023 Earnings Call Transcript
Delcath Systems Inc. (NASDAQ:DCTH ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants Gerard Michel - Chief Executive Officer Anthony Dias - Vice President, Finance Kevin Muir - General Manager, U.S. Interventional Oncology David Hoffman - General Counsel, Chief Compliance Officer Conference Call Participants Yale Jen - Laidlaw & Co. Swayampakula Ramakanth - HC Wainwright Bill Maughan - Canaccord Genuity Operator Good day and welcome to the Delcath Systems Reports First Quarter Fiscal 2023 Financial Results Call. All participants will be in listen-only mode, and should you need assistance, please signal a conference specialist by pressing the star key followed by zero.
Delcath Systems (DCTH) Q1 2023 Earnings Call Transcript
Delcath Systems Inc. (NASDAQ:DCTH ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants Gerard Michel - Chief Executive Officer Anthony Dias - Vice President, Finance Kevin Muir - General Manager, U.S. Interventional Oncology David Hoffman - General Counsel, Chief Compliance Officer Conference Call Participants Yale Jen - Laidlaw & Co. Swayampakula Ramakanth - HC Wainwright Bill Maughan - Canaccord Genuity Operator Good day and welcome to the Delcath Systems Reports First Quarter Fiscal 2023 Financial Results Call. All participants will be in listen-only mode, and should you need assistance, please signal a conference specialist by pressing the star key followed by zero.
05/03 08:30 EST - PRNewsWire
Delcath Systems to Host First Quarter 2023 Results
NEW YORK , May 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 12, 2023, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2023. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
Delcath Systems to Host First Quarter 2023 Results
NEW YORK , May 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 12, 2023, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2023. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
11/08 13:33 EST - Seeking Alpha
Delcath Systems, Inc. (DCTH) Q3 2022 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:00 AM ET Delcath Systems, Inc. (NASDAQ:DCTH ) Q3 2022 Earnings Conference Call November 08, 2022, 08:30 AM ET Company Participants Gerard Michel - CEO Anthony Dias - VP of Finance Johnny John - VP, Clinical Development & Medical Affairs Kevin Muir - VP, Commercial Operations David Hoffman - General Counsel, Corporate Secretary and Chief Compliance Officer Conference Call Participants Sam Eiber - BTIG Scott Henry - ROTH Capital Yale Jen - Laidlaw & Company Bill Maughan - Canaccord Genuity Operator Good day, and welcome to the Delcath Systems Third Quarter 2022 Financial Results Conference Call. All participants will be in listen-only mode.
Delcath Systems, Inc. (DCTH) Q3 2022 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:00 AM ET Delcath Systems, Inc. (NASDAQ:DCTH ) Q3 2022 Earnings Conference Call November 08, 2022, 08:30 AM ET Company Participants Gerard Michel - CEO Anthony Dias - VP of Finance Johnny John - VP, Clinical Development & Medical Affairs Kevin Muir - VP, Commercial Operations David Hoffman - General Counsel, Corporate Secretary and Chief Compliance Officer Conference Call Participants Sam Eiber - BTIG Scott Henry - ROTH Capital Yale Jen - Laidlaw & Company Bill Maughan - Canaccord Genuity Operator Good day, and welcome to the Delcath Systems Third Quarter 2022 Financial Results Conference Call. All participants will be in listen-only mode.
09/01 16:15 EST - PRNewsWire
Delcath Systems to Participate at the H.C. Wainwright 24th Annual Global Investor Conference on September 12 and 13, 2022
NEW YORK , Sept. 1, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C.
Delcath Systems to Participate at the H.C. Wainwright 24th Annual Global Investor Conference on September 12 and 13, 2022
NEW YORK , Sept. 1, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C.
08/08 14:56 EST - Seeking Alpha
Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q2 2022 Results - Earnings Call Transcript
Delcath Systems, Inc. (NASDAQ:DCTH ) Q2 2022 Earnings Conference Call August 8, 2022 8:30 AM ET Company Participants David Hoffman - General Counsel Gerard Michel - Chief Executive Officer Anthony Dias - Vice President of Finance Johnny John - Senior Vice President of Medical Affairs and Clinical Development Kevin Muir - Vice President of Commercial Operations John Purpura - Chief Operating Officer Conference Call Participants Scott Henry - Roth Capital Marie Sebalt - BTIG Bill Maughan - Canaccord Genuity Yale Jen - Laidlaw & Co Swayampakula Ramakanth - HC Wainright Operator Good morning, and welcome to the Delcath Systems Second Quarter Fiscal 2022 Financial Results Conference Call. All participants' will be in listen-only mode.
Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q2 2022 Results - Earnings Call Transcript
Delcath Systems, Inc. (NASDAQ:DCTH ) Q2 2022 Earnings Conference Call August 8, 2022 8:30 AM ET Company Participants David Hoffman - General Counsel Gerard Michel - Chief Executive Officer Anthony Dias - Vice President of Finance Johnny John - Senior Vice President of Medical Affairs and Clinical Development Kevin Muir - Vice President of Commercial Operations John Purpura - Chief Operating Officer Conference Call Participants Scott Henry - Roth Capital Marie Sebalt - BTIG Bill Maughan - Canaccord Genuity Yale Jen - Laidlaw & Co Swayampakula Ramakanth - HC Wainright Operator Good morning, and welcome to the Delcath Systems Second Quarter Fiscal 2022 Financial Results Conference Call. All participants' will be in listen-only mode.